GSK posted higher profit as sales for its specialty treatments for HIV, cancer and asthma beat expectations, offsetting lower ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

The settlement, which calls for Gilead to pay the U.S. nearly $177 million and the balance to various states, was approved ...

Patients in historically redlined neighborhoods experience significantly longer delays in achieving HIV viral suppression ...

If you support maintaining the U.S. approach to fighting HIV/AIDS, you should welcome the DOGE review to ensure that programs ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Demonstrators gathered Thursday on the steps of the Department of Health and Human Services (HHS) building for a “die-in” ...

A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now ...

A safety analysis of mRNA vaccination in a phase 1, randomized, open-label clinical trial evaluated the safety and ...

Cuts to sexual health clinics could make eliminating new HIV cases in England by 2030 “impossible”, politicians have warned.

Dolutegravir is recommended by the World Health Organization (WHO) for infants, children and adults and is the preferred HIV ...

The Uganda AIDS Commission (UAC) has reported a continued decline in new HIV infections, though the country still falls short ...